Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
November 22, 2023 08:00 ET
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
November 21, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 15, 2023 16:45 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 13, 2023 08:00 ET
|
Sagimet Biosciences Inc.
On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024 Two abstracts, including late-breaker, accepted at the American...
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
November 13, 2023 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
November 10, 2023 08:30 ET
|
Sagimet Biosciences Inc.
Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver...
Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health
November 10, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Data to be featured in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting®Analyses from comprehensive set of noninvasive tests used in MAESTRO-NASH...
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
November 10, 2023 07:30 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
November 08, 2023 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
November 06, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Priority Review of resmetirom new drug application underway in the U.S.Bill Sibold appointed Chief Executive Officer of Madrigal in September 2023$500 million financing provides Madrigal with funds to...